Browse

Valneva’s Shigella vaccine has been shown to reduce cases of intestinal infection, hitting the key endpoint of a phase 2 trial.

Argenx has struck a deal to acquire Unnatural Products for $550 million upfront, snapping up the Merck & Co.- and Novartis-partnered biotech to add oral peptide capabilities.

Vir Biotechnology announced that its chronic hepatitis D treatment met its primary goal in the first of three late‑stage studies. The trial evaluated a once‑monthly combination therapy that include…